{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:15:56Z","timestamp":1791353756084,"version":"4.3.1"},"reference-count":43,"publisher":"American Association for Cancer Research (AACR)","issue":"2","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Osteosarcoma is the most frequent primary bone malignant tumor that develops mainly in children and adolescents. Despite recent improvements in chemotherapy and surgery, survival rate is \u223c50% after 5 years. Osteoprotegerin (OPG) is a potent inhibitor of osteoclast differentiation and activation, but its use as therapeutic agent in cancer-associated osteolysis remains controversial due to its ability to bind and inhibit the apoptotic effect of tumor necrosis factor\u2013related apoptosis-inducing ligand (TRAIL) on tumor cells. The therapeutic effects of full-length OPG (1-401) and OPG 1-194 lacking its heparin-binding domain delivered by nonviral gene therapy were compared in a murine model of osteolytic osteosarcoma. Tumor incidence, progression, and associated bone lesions were significantly diminished in the OPG 1-194 group, but not in the OPG 1-401 group, compared with controls. As receptor activator of nuclear factor-\u03baB ligand (RANKL), TRAIL, and glycosaminoglycans (GAG) were shown to be overexpressed in osteosarcoma environment compared with control tissue, OPG 1-401 bioactivity may be modulated by one of these protagonists. Surface plasmon resonance analyses performed with OPG, TRAIL, and GAGs revealed that TRAIL binds both forms of OPG with the same affinity. In addition, as OPG 1-194 and OPG 1-401 similarly inhibit TRAIL-induced apoptosis, it suggests that TRAIL is not involved in the modulation of OPG bioactivity. However, as GAGs inhibit OPG 1-401 but not OPG 1-194 binding to TRAIL or to RANKL, they may represent potent regulators of OPG availability and antitumor activity in bone tumor microenvironment. [Cancer Res 2009;69(2):526\u201336]<\/jats:p>","DOI":"10.1158\/0008-5472.can-08-2648","type":"journal-article","created":{"date-parts":[[2009,1,15]],"date-time":"2009-01-15T08:52:56Z","timestamp":1232009576000},"page":"526-536","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Glycosaminoglycans as Potential Regulators of Osteoprotegerin Therapeutic Activity in Osteosarcoma"],"prefix":"10.1158","volume":"69","author":[{"given":"Francois","family":"Lamoureux","sequence":"first","affiliation":[{"name":"1Institut National de la Sante et de la Recherche Medicale ERI 7;"},{"name":"2Universite\u0301 de Nantes, Nantes Atlantique Universite\u0301s, Laboratoire de Physiopathologie de la Re\u0301sorption Osseuse et The\u0301rapie des Tumeurs Osseuses Primitives;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gae\u0308lle","family":"Picarda","sequence":"additional","affiliation":[{"name":"1Institut National de la Sante et de la Recherche Medicale ERI 7;"},{"name":"2Universite\u0301 de Nantes, Nantes Atlantique Universite\u0301s, Laboratoire de Physiopathologie de la Re\u0301sorption Osseuse et The\u0301rapie des Tumeurs Osseuses Primitives;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Garrigue-Antar","sequence":"additional","affiliation":[{"name":"3Institut National de la Sante et de la Recherche Medicale U892;"},{"name":"4Universite\u0301 de Nantes, IFR26;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Baud'huin","sequence":"additional","affiliation":[{"name":"1Institut National de la Sante et de la Recherche Medicale ERI 7;"},{"name":"2Universite\u0301 de Nantes, Nantes Atlantique Universite\u0301s, Laboratoire de Physiopathologie de la Re\u0301sorption Osseuse et The\u0301rapie des Tumeurs Osseuses Primitives;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Trichet","sequence":"additional","affiliation":[{"name":"1Institut National de la Sante et de la Recherche Medicale ERI 7;"},{"name":"2Universite\u0301 de Nantes, Nantes Atlantique Universite\u0301s, Laboratoire de Physiopathologie de la Re\u0301sorption Osseuse et The\u0301rapie des Tumeurs Osseuses Primitives;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre\u0301","family":"Vidal","sequence":"additional","affiliation":[{"name":"7Institut National de la Sante et de la Recherche Medicale UMR 484, Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Miot-Noirault","sequence":"additional","affiliation":[{"name":"7Institut National de la Sante et de la Recherche Medicale UMR 484, Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Pitard","sequence":"additional","affiliation":[{"name":"5In-Cell-Art;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Heymann","sequence":"additional","affiliation":[{"name":"1Institut National de la Sante et de la Recherche Medicale ERI 7;"},{"name":"2Universite\u0301 de Nantes, Nantes Atlantique Universite\u0301s, Laboratoire de Physiopathologie de la Re\u0301sorption Osseuse et The\u0301rapie des Tumeurs Osseuses Primitives;"},{"name":"6CHU, Ho\u0302tel Dieu, Nantes, France and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franc\u0327oise","family":"Re\u0301dini","sequence":"additional","affiliation":[{"name":"1Institut National de la Sante et de la Recherche Medicale ERI 7;"},{"name":"2Universite\u0301 de Nantes, Nantes Atlantique Universite\u0301s, Laboratoire de Physiopathologie de la Re\u0301sorption Osseuse et The\u0301rapie des Tumeurs Osseuses Primitives;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2009,1,15]]},"reference":[{"key":"2022061701353070800_B1","doi-asserted-by":"crossref","unstructured":"Lamoureux F, Trichet V, Chipoy C, Blanchard F, Gouin F, Redini F. Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies. Expert Rev Anticancer Ther\u20082007; 7: 169\u201381.","DOI":"10.1586\/14737140.7.2.169"},{"key":"2022061701353070800_B2","doi-asserted-by":"crossref","unstructured":"Picci P. Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis\u20082007; 2: 6.","DOI":"10.1186\/1750-1172-2-6"},{"key":"2022061701353070800_B3","unstructured":"Guise TA. The vicious cycle of bone metastases. J Musculoskelet Neuronal Interact\u20082002; 2: 570\u20132."},{"key":"2022061701353070800_B4","doi-asserted-by":"crossref","unstructured":"Grimaud E, Soubigou L, Couillaud S, et al. Receptor activator of nuclear factor \u03baB ligand (RANKL)\/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol\u20082003; 163: 2021\u201331.","DOI":"10.1016\/S0002-9440(10)63560-2"},{"key":"2022061701353070800_B5","doi-asserted-by":"crossref","unstructured":"Blanchard F, Chipoy C. Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases? Drug Discov Today\u20082005; 10: 197\u2013204.","DOI":"10.1016\/S1359-6446(04)03309-4"},{"key":"2022061701353070800_B6","doi-asserted-by":"crossref","unstructured":"Wittrant Y, Theoleyre S, Chipoy C, et al. RANKL\/RANK\/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta\u20082004; 1704: 49\u201357.","DOI":"10.1016\/j.bbcan.2004.05.002"},{"key":"2022061701353070800_B7","doi-asserted-by":"crossref","unstructured":"Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell\u20081998; 93: 165\u201376.","DOI":"10.1016\/S0092-8674(00)81569-X"},{"key":"2022061701353070800_B8","doi-asserted-by":"crossref","unstructured":"Body JJ, Greipp P, Coleman RE, et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer\u20082003; 97: 887\u201392.","DOI":"10.1002\/cncr.11138"},{"key":"2022061701353070800_B9","unstructured":"Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res\u20082001; 61: 4432\u20136."},{"key":"2022061701353070800_B10","doi-asserted-by":"crossref","unstructured":"Lamoureux F, Richard P, Wittrant Y, et al. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Res\u20082007; 67: 7308\u201318.","DOI":"10.1158\/0008-5472.CAN-06-4130"},{"key":"2022061701353070800_B11","doi-asserted-by":"crossref","unstructured":"Holen I, Shipman CM. Role of osteoprotegerin (OPG) in cancer. Clin Sci Lond\u20082006; 110: 279\u201391.","DOI":"10.1042\/CS20050175"},{"key":"2022061701353070800_B12","doi-asserted-by":"crossref","unstructured":"Fisher JL, Thomas-Mudge RJ, Elliott J, et al. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. Cancer Res\u20082006; 66: 3620\u20138.","DOI":"10.1158\/0008-5472.CAN-05-3119"},{"key":"2022061701353070800_B13","doi-asserted-by":"crossref","unstructured":"Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem\u20081998; 273: 14363\u20137.","DOI":"10.1074\/jbc.273.23.14363"},{"key":"2022061701353070800_B14","doi-asserted-by":"crossref","unstructured":"Nyambo R, Cross N, Lippitt J, et al. Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis. J Bone Miner Res\u20082004; 19: 1712\u201321.","DOI":"10.1359\/JBMR.040703"},{"key":"2022061701353070800_B15","doi-asserted-by":"crossref","unstructured":"Neville-Webbe HL, Cross NA, Eaton CL, et al. Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res Treat\u20082004; 86: 269\u201379.","DOI":"10.1023\/B:BREA.0000036900.48763.b3"},{"key":"2022061701353070800_B16","unstructured":"Shipman CM, Croucher PI. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand\/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res\u20082003; 63: 912\u20136."},{"key":"2022061701353070800_B17","doi-asserted-by":"crossref","unstructured":"Lamoureux F, Baud'huin M, Duplomb L, Heymann D, Redini F. Proteoglycans: key partners in bone cell biology. Bioessays\u20082007; 29: 758\u201371.","DOI":"10.1002\/bies.20612"},{"key":"2022061701353070800_B18","doi-asserted-by":"crossref","unstructured":"Yip GW, Smollich M, Gotte M. Therapeutic value of glycosaminoglycans in cancer. Mol Cancer Ther\u20082006; 5: 2139\u201348.","DOI":"10.1158\/1535-7163.MCT-06-0082"},{"key":"2022061701353070800_B19","doi-asserted-by":"crossref","unstructured":"Standal T, Seidel C, Hjertner O, et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood\u20082002; 100: 3002\u20137.","DOI":"10.1182\/blood-2002-04-1190"},{"key":"2022061701353070800_B20","doi-asserted-by":"crossref","unstructured":"Mosheimer BA, Kaneider NC, Feistritzer C, et al. Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. J Clin Endocrinol Metab\u20082005; 90: 2964\u201371.","DOI":"10.1210\/jc.2004-1895"},{"key":"2022061701353070800_B21","doi-asserted-by":"crossref","unstructured":"Theoleyre S, Kwan Tat S, Vusio P, et al. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor \u03baB ligand (RANKL) and RANK. Biochem Biophys Res Commun\u20082006; 347: 460\u20137.","DOI":"10.1016\/j.bbrc.2006.06.120"},{"key":"2022061701353070800_B22","doi-asserted-by":"crossref","unstructured":"Kamijo A, Koshino T, Uesugi M, Nitto H, Saito T. Inhibition of lung metastasis of osteosarcoma cell line POS-1 transplanted into mice by thigh ligation. Cancer Lett\u20082002; 188: 213\u20139.","DOI":"10.1016\/S0304-3835(02)00433-0"},{"key":"2022061701353070800_B23","doi-asserted-by":"crossref","unstructured":"Wittrant Y, Lamoureux F, Mori K, et al. RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells. Int J Oncol\u20082006; 28: 261\u20139.","DOI":"10.3892\/ijo.28.1.261"},{"key":"2022061701353070800_B24","doi-asserted-by":"crossref","unstructured":"Richard P, Bossard F, Desigaux L, Lanctin C, Bello-Roufai M, Pitard B. Amphiphilic block copolymers promote gene delivery in vivo to pathological skeletal muscles. Hum Gene Ther\u20082005; 16: 1318\u201324.","DOI":"10.1089\/hum.2005.16.1318"},{"key":"2022061701353070800_B25","doi-asserted-by":"crossref","unstructured":"Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol\u20082002; 3: RESEARCH0034.","DOI":"10.1186\/gb-2002-3-7-research0034"},{"key":"2022061701353070800_B26","doi-asserted-by":"crossref","unstructured":"Nicolas C, Borel M, Maurizis JC, et al. Synthesis of N-quaternary ammonium [3H] and [99mTc]polyazamacrocycles, potential radiotracers for cartilage imaging. J Labelled Cpd Radiopharm\u20082000; 43: 585\u201394.","DOI":"10.1002\/(SICI)1099-1344(200005)43:6<585::AID-JLCR343>3.0.CO;2-H"},{"key":"2022061701353070800_B27","doi-asserted-by":"crossref","unstructured":"Corey E, Brown LG, Kiefer JA, et al. Osteoprotegerin in prostate cancer bone metastasis. Cancer Res\u20082005; 65: 1710\u20138.","DOI":"10.1158\/0008-5472.CAN-04-2033"},{"key":"2022061701353070800_B28","doi-asserted-by":"crossref","unstructured":"Canon JR, Roudier M, Bryant R, et al. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis\u20082008; 25: 119\u201329.","DOI":"10.1007\/s10585-007-9127-1"},{"key":"2022061701353070800_B29","doi-asserted-by":"crossref","unstructured":"Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG\/OCIF inhibits osteoclastogenesis in vitro. Endocrinology\u20081998; 139: 1329\u201337.","DOI":"10.1210\/endo.139.3.5837"},{"key":"2022061701353070800_B30","doi-asserted-by":"crossref","unstructured":"Yamaguchi K, Kinosaki M, Goto M, et al. Characterization of structural domains of human osteoclastogenesis inhibitory factor. J Biol Chem\u20081998; 273: 5117\u201323.","DOI":"10.1074\/jbc.273.9.5117"},{"key":"2022061701353070800_B31","doi-asserted-by":"crossref","unstructured":"Vitovski S, Phillips JS, Sayers J, Croucher PI. Investigating the interaction between osteoprotegerin and receptor activator of NF-\u03baB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J Biol Chem\u20082007; 282: 31601\u20139.","DOI":"10.1074\/jbc.M706078200"},{"key":"2022061701353070800_B32","unstructured":"Holen I, Croucher PI, Hamdy FC, Eaton CL. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res\u20082002; 62: 1619\u201323."},{"key":"2022061701353070800_B33","doi-asserted-by":"crossref","unstructured":"Cheng X, Kinosaki M, Takami M, Choi Y, Zhang H, Murali R. Disabling of receptor activator of nuclear factor-\u03baB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo. J Biol Chem\u20082004; 279: 8269\u201377.","DOI":"10.1074\/jbc.M309690200"},{"key":"2022061701353070800_B34","doi-asserted-by":"crossref","unstructured":"Heath DJ, Vanderkerken K, Cheng X, et al. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma. Cancer Res\u20082007; 67: 202\u20138.","DOI":"10.1158\/0008-5472.CAN-06-1287"},{"key":"2022061701353070800_B35","doi-asserted-by":"crossref","unstructured":"Croucher PI, Shipman CM, Lippitt J, et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood\u20082001; 98: 3534\u201340.","DOI":"10.1182\/blood.V98.13.3534"},{"key":"2022061701353070800_B36","unstructured":"Vanderkerken K, De Leenheer E, Shipman C, et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res\u20082003; 63: 287\u20139."},{"key":"2022061701353070800_B37","doi-asserted-by":"crossref","unstructured":"Zhang J, Dai J, Qi Y, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest\u20082001; 107: 1235\u201344.","DOI":"10.1172\/JCI11685"},{"key":"2022061701353070800_B38","doi-asserted-by":"crossref","unstructured":"Truneh A, Sharma S, Silverman C, et al. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J Biol Chem\u20082000; 275: 23319\u201325.","DOI":"10.1074\/jbc.M910438199"},{"key":"2022061701353070800_B39","doi-asserted-by":"crossref","unstructured":"Shin J, Kim YM, Li SZ, Lim SK, Lee W. Structure-function of the TNF receptor-like cysteine-rich domain of osteoprotegerin. Mol Cells\u20082008; 25: 352\u20137.","DOI":"10.1016\/S1016-8478(23)17592-3"},{"key":"2022061701353070800_B40","doi-asserted-by":"crossref","unstructured":"Irie A, Takami M, Kubo H, Sekino-Suzuki N, Kasahara K, Sanai Y. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity. Bone\u20082007; 41: 165\u201374.","DOI":"10.1016\/j.bone.2007.04.190"},{"key":"2022061701353070800_B41","doi-asserted-by":"crossref","unstructured":"Shinmyouzu K, Takahashi T, Ariyoshi W, Ichimiya H, Kanzaki S, Nishihara T. Dermatan sulfate inhibits osteoclast formation by binding to receptor activator of NF-\u03baB ligand. Biochem Biophys Res Commun\u20082007; 354: 447\u201352.","DOI":"10.1016\/j.bbrc.2006.12.221"},{"key":"2022061701353070800_B42","doi-asserted-by":"crossref","unstructured":"Borset M, Hjertner O, Yaccoby S, Epstein J, Sanderson RD. Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. Blood\u20082000; 96: 2528\u201336.","DOI":"10.1182\/blood.V96.7.2528.h8002528_2528_2536"},{"key":"2022061701353070800_B43","doi-asserted-by":"crossref","unstructured":"Schneeweis LA, Willard D, Milla ME. Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-\u03baB ligand. J Biol Chem\u20082005; 280: 41155\u201364.","DOI":"10.1074\/jbc.M506366200"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/69\/2\/526\/2614743\/526.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/69\/2\/526\/2614743\/526.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T03:32:58Z","timestamp":1709955178000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/69\/2\/526\/550003\/Glycosaminoglycans-as-Potential-Regulators-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,15]]},"references-count":43,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2009,1,15]]},"published-print":{"date-parts":[[2009,1,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-08-2648","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,15]]}}}